The Intrinsic Capacity, Frailty and Sarcopenia Research (ICFSR) Task Force convened in March 2025 to discuss geroscience-oriented pre-clinical and clinical trials aimed at promoting healthy aging. Key topics included the use of aging biomarkers in clinical trials, senotherapeutics, metabolism-targeting medications, and therapeutic strategies beyond pharmacological approaches. The discussions highlighted the growing interest in, and accumulating evidence for, geroscience interventions. Several future challenges were identified, including the need for a deeper understanding of the biology of aging and the validation of aging biomarkers against relevant clinical outcomes, such as frailty and intrinsic capacity. Furthermore, to accelerate innovation in the field, there is a need to enhance clinical trial methodologies and harmonization—for example, by defining a minimum common dataset of biological, physiological, and clinical factors for geroscience clinical studies—and to foster a paradigm shift, particularly among regulatory authorities.
Tagliafico et al. (2026) studied this question.